Anti-tumor therapy for targeting aryl hydrocarbon receptor
10.3969/j.issn.1001-1978.2016.05.004
- VernacularTitle:以芳香烃受体为药物靶点的肿瘤治疗研究
- Author:
Ying LIU
;
Hongying ZHANG
;
Tao TANG
;
Feifei LIU
;
Wei WU
;
Ying LUO
;
Jihong ZHANG
- Publication Type:Journal Article
- Keywords:
aryl hydrocarbon receptor;
tumor;
ligand;
targeted drugs;
mechanism;
present state
- From:
Chinese Pharmacological Bulletin
2016;32(5):607-611,612
- CountryChina
- Language:Chinese
-
Abstract:
Aryl hydrocarbon receptor ( AhR) is a ligand-depend-ent transcription factor that mediates the toxicity of xenobiotic ligands like 2,3,7,8-tetrachlorodibenzo-p-dioxins(TCDDs). AhR influences tumor growth, survival, migration and invasion by regulating proliferation, apoptosis and immune metabolism of tumor cells. AhR has two ways to regulate tumor development, and ligands like polycyclic aromatic hydrocarbons( PAHs) , hal-ogenated aromatic hydrocarbons( HAHs) can induce tumorigene-sis. However, some compounds such as benzothiazole and amin-oflavone can activate AhR, which suppresses the tumor progres-sion and suggests that AhR may be a novel drug target for anti-tumor therapy. The paper discussed the role of AhR in tumori-genesis, the mechanism of the drugs targetting AhR and the sta-tus of studying AhR as a potential target in anticancer therapy.
